Understanding swiss drug policy change and the introduction of heroin maintenance treatment

European Addiction Research

Volumn 20, Issue 4, 2014, Pages 200-207

  Khan, Riaz ^a   Khazaal, Yasser ^a   Thorens, Gabriel ^a   Zullino, Daniele ^a   Uchtenhagen, Ambros ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

Author keywords

Addictions; Drug policy; Harm reduction; Heroin; Knowledge brokering; Opiate prescription

Indexed keywords

DIAMORPHINE; NEW DRUG; NARCOTIC AGENT;

DRUG DEPENDENCE TREATMENT; HEALTH CARE POLICY; HUMAN; MAINTENANCE THERAPY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SWITZERLAND; CLINICAL MEDICINE; COMPREHENSION; HARM REDUCTION; HEALTH INSURANCE; HEROIN DEPENDENCE; KNOWLEDGE; POLITICAL SYSTEM; SOCIAL PSYCHOLOGY; MAINTENANCE CHEMOTHERAPY; OPIATE SUBSTITUTION TREATMENT; PROCEDURES; TREATMENT OUTCOME;

HARM REDUCTION; HEALTH POLICY; HEROIN; HEROIN DEPENDENCE; HUMANS; MAINTENANCE CHEMOTHERAPY; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; SWITZERLAND; TREATMENT OUTCOME;

EID: 84893666411     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000357234     Document Type: Review

References (42)

1. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A: Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001; 358: 1417-1423
2. van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM: Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. BMJ 2003; 327: 310-312. (Pubitemid 36966616)
3. Uchtenhagen A, Dobler-Mikola A, Steffen T, Gutzwiller R, Blättler R, Pfeifer S: Prescriptions of Narcotics for Heroin Addicts. Main Results of the Swiss National Cohort Study. Basel, Karger, 1999
4. Uchtenhagen A, Gutzwiller F, Dobler-Mikola AD, Steffen T: Programme for a medical prescription of narcotics. A synthesis of results. Eur Addict Res 1997; 3: 160-163
5. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT: Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361: 777-786
6. Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, et al: Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): A randomised trial. Lancet 2010; 375: 1885-1895
7. Naber D, Haasen C: Das Bundesdeutsche Modellprojekt zur heroingestützten Behandlung Opiatabhängiger. Abschlussbericht zur klinischen Vergleichsstudie zur Heroin- und Methadonbehandlung. Hamburg, ZIS der Universität Hamburg, 2006
8. Ferri M, Davoli M, Perucci CA: Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2011;CD003410
9. Strang J, Groshkova T, Metrebian N: New heroin assisted treatment. Recent evidence and current practices of supervised injected heroin treatment in Europe and beyond. Luxembourg, Publications Office of the European Union, 2012
10. Uchtenhagen A: Heroin-Assisted treatment in Switzerland: A case study in policy change. Addiction 2010; 105: 29-37
11. Perneger TV, Giner F, del Rio M, Mino A: Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-18. (Pubitemid 28333818)
12. Bammer G, van den Brink W, Gschwend P, Hendriks V, Rehm J: What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev 2003; 22: 363-371
13. Sprumont D: Ethical evaluation of heroinprescription research: An insider's view. Am J Bioeth 2002; 2: 63-64
14. Ostini R, Bammer G, Dance PR, Goodin RE: The ethics of experimental heroin maintenance. J Med Ethics 1993; 19: 175-182. (Pubitemid 23297055)
15. Swiss Federal Council: Bundesratsbeschluss über Massnahmen des Bundes zur Verminderung der Drogenprobleme vom 20. Februar 1991. Bern, Bundeskanzlei, 1991
16. Federal Office of Public Health: Massnahmen des Bundes zur Verminderung der Drogenprobleme: Ein Grundlagenpapier des Bundesamtes für Gesundheitswesen. Bern, Federal Office of Public Health, 1991
17. Ali R, Auriacombe M, Casas M, Cottler L, Farrell M, Kleiber D, Kreuzer AR, Ogbome A, Rehm J, Ward P: Report of the External Panel on the Evaluation of the Swiss Scientific Studies of Medically Prescribed Narcotics to Drug Addicts. Geneva, Report to the World Health Organisation, 1998
18. Canadian Health Services Research Foundation. The theory and practice of knowledge brokering in Canada's health system. 2003
19. Jackson-Bowers E, Kalucy L, Mc Intyre E: Focus on. Focus on knowledge brokering. Adelaide, Primary Health Care Research and Information Service, 2006
20. van Kammen J, de Savigny D, Sewankambo N: Using knowledge brokering to promote evidence-based policy-making: The need for support structures. Bull World Health Organ 2006; 84: 608-612. (Pubitemid 44338244)
21. Ritter A: How do drug policy makers access research evidence? Int J Drug Policy 2009; 20: 70-75
22. Anderson LM, Brownson RC, Fullilove MT, Teutsch SM, Novick LF, Fielding J, Land GH: Evidence-based public health policy and practice: Promises and limits. Am J Prev Med 2005; 28: 226-230. (Pubitemid 40724385)
23. Hanney SR, Gonzalez-Block MA, Buxton MJ, Kogan M: The utilisation of health research in policy-making: Concepts, examples and methods of assessment. Health Res Policy Syst 2003; 1: 2
24. Gregrich RJ: A note to researchers: Communicating science to policy makers and practitioners. J Subst Abuse Treat 2003; 25: 233-237. (Pubitemid 37518383)
25. Uchtenhagen A: The role of coalitions in drug policy. Some theoretical and observational considerations. Adicciones 2011; 23: 183-187
26. Sabatier P: The advocacy coalition framework: Revisions and relevance for Europe. J Eur Public Policy 1998; 5: 98-130
27. Freeman L: The Development of Social Network Analysis. Vancouver, Empirical Press, 2006
28. May CR, Mair F, Finch T, MacFarlane A, Dowrick C, Treweek S, Rapley T, Ballini L, Ong BN, Rogers A, et al: Development of a theory of implementation and integration: Normalization Process Theory. Implement Sci 2009; 4: 29
29. Wejnert B: Integrating models of diffusion of innovations: A conceptual framework. Annu Rev Sociol 2002; 28: 297-306
30. Rogers EM: Diffusion of Innovations, ed 5 New York, Free Press, 2003
31. Waddell S: Societal Learning and Change. Sheffield, Greenleaf Publishing, 2005
32. Law J, Hassard J: Actor Network Theory and After. Oxford, Blackwell, 1999
33. Latour B: Reassembling the Social: An Introduction to Actor-Network-Theory. Oxford, Oxford University Press, 2005
34. Callon M, Lascoumes P, Barthe Y: Acting in an Uncertain World. An Essay on Technical Democracy. Cambridge, MIT Press, 2009
35. Serduelt U: Politiknetzwerke in der städtischen Drogenpolitik von Bern, Chur, St. Gallen und Zürich. Zurich, University of Zurich, 2000
36. Kübler D: Beyond nimbyism. Urban conflict resolution in Swiss drug policies; in Khan U: Participation beyond the Ballot Box European Case Studies in State-Citizen Dialogue. London, UCL Press, 1999, pp 43-64
37. Kübler D: Politique de la drogue dans les villes suisses entre ordre et santé. Analyse des conflits de mise en oeuvre. Paris, L'Harmattan, 2000
38. Kübler D: Understanding policy change with the advocacy coalition framework: An application to Swiss Drug Policy. J Eur Public Policy 2001; 8
39. Grob P: Zürcher 'Needle Park'. Ein Stück Drogengeschichte und -politik 1968-2008 Zurich, Chronos, 2012
40. Mino A: Scientific Analysis of the Studies on Heroin or Morphine Controlled Delivery. Bern, 1990
41. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A: General study design and implementation rules. Foundation for social therapy, the connection between research and practice in drug therapy. Drogalkohol 1994; 187-198
42. Subcomission for Drug Issues: Drug Policy Scenarios. Bern, 1996.